Chronic pancreatitis (CP), characterized by pancreatic fibrosis, is a recurrent, progressive and irreversible disease. Activation of the pancreatic stellate cells (PSCs) is considered a core event in pancreatic fibrosis. In this study, we investigated the role of hydrogen peroxide-inducible clone-5 (Hic-5) in CP. Analysis of the human pancreatic tissue samples revealed that Hic-5 was overexpressed in patients with CP and was extremely low in healthy pancreas. Hic-5 was significant up-regulated in the activated primary PSCs independently from transforming growth factor beta stimulation. CP induced by cerulein injection was ameliorated in Hic-5 knockout (KO) mice, as shown by staining of tissue level. Simultaneously, the activation ability of the primary PSCs from Hic-5 KO mice was significantly attenuated. We also found that the Hic-5 up-regulation by cerulein activated the NF-κB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as α-SMA and Col1a1. Therefore, we determined whether suppressing NF-κB/p65 alleviated CP by treating mice with the NF-κB/p65 inhibitor triptolide in the cerulein-induced CP model and found that pancreatic fibrosis was alleviated by NF-κB/p65 inhibition. These findings provide evidence for Hic-5 as a therapeutic target that plays a crucial role in regulating PSCs activation and pancreatic fibrosis.
| INTRODUC TI ON
Chronic pancreatitis (CP) is a recurrent, progressive and irreversible inflammatory disease of the pancreas with a long course and poor prognosis. The main clinical manifestations of CP are abdominal pain, indigestion, steatorrhea and diabetes. 1, 2 Importantly, patients with CP are at a higher risk for pancreatic cancer, one of the most devastating diseases. [3] [4] [5] The main pathophysiological process underlying CP is the gradual replacement of the normal pancreatic tissue with atrophy and/or fibrosis, which leads to progressive loss of endocrine and exocrine regions, evident by pancreatic parenchymal atrophy and interstitial fibrosis. 6, 7 Importantly, the mechanism underlying pancreatic fibrosis, a key pathological change in CP, is not fully understood.
The inflammatory microenvironment in CP includes a variety of cells, including pancreatic acinar cells, macrophages and pancreatic stellate cells (PSCs). In the normal pancreas, the few PSCs that are present in the connective tissue are quiescent. In this state, the PSCs are rich in vitamin A-containing lipid droplets, and only a small amount of extracellular matrix (ECM) components are secreted. 8 However, during CP, PSCs are activated as demonstrated by their morphology resembling fibroblasts. Additionally, the lipid droplets are either decreased in number or absent, there is active proliferation, and the secretion of ECM components such as type I and type III collagen is increased, which not only aggravates pancreatic fibrosis but also constitutes a barrier to drug penetration. 9, 10 Therefore, activation of PSCs is considered a core event in pancreatic fibrosis. 11, 12 Epithelial mesenchymal transition (EMT) is a biological phenomenon in which epithelial cells lose epithelial properties to obtain stromal cell phenotypes. Recent studies confirmed the role of EMT in fibrosis of organs such as the lungs and the liver. 13, 14 Downregulation of epithelial markers such as E-cadherin and cytokeratin and changes in cell morphology and migration are important features of EMT. 12 Studies demonstrated that the processes underlying PSCs activation were similar to those observed during EMT, 15 suggesting that the inhibition of PSCs activation is a promising target for an optimal treatment approach in CP.
Hydrogen peroxide-inducible clone-5 (Hic-5), also known as transforming growth factor beta (TGF-β)-1-induced transcript 1, is A LIM(Lin-11, Isl-1 and Mec-3)-containing adhesion scaffold protein with homology to paxillin. 16 The N-terminal region of Hic-5 comprises four LD motifs (leucine-aspartic acid motifs) that are rich in Leu and Asp, whereas the C-terminal region comprises four LIM domains with two zinc fingers. 17 Therefore, Hic-5 not only has the ability to control cytoskeletal organization but also acts as an adaptor and nuclear receptor coactivator. 18, 19 Hic-5 was shown to be involved in the regulation of various cellular processes including proliferation, migration and differentiation, ageing, wound healing, vascular injury, tumorigenesis, steroid activity, apoptosis and signal integration. 19 Recent studies revealed that Hic-5 plays an important role in several fibrotic diseases. First, Hic-5 was shown to be a key link in the formation of ECM in the abnormal glomeruli of glomerular sclerosis. 20 Hic-5 was also found to be positively correlated with the expression of the hepatic stellate cells activation marker α-smooth muscle actin (α-SMA) during liver fibrosis. 21 Furthermore, Hic-5 plays a key role in disorders such as intestinal fibrosis by regulating the differentiation of myofibroblasts and the expression of ECM proteins. 22 However, the mechanism underlying Hic-5-mediated regulation of CP has not been determined.
In the current study, we investigated the effect of Hic-5 by knocking out Hic-5 in a mice model of CP and found that, in addition to changes in fibrosis-related gene expression, the NF-κB/p65 subunit and interleukin (IL)-6 levels were decreased significantly as well.
We also utilized primary PSCs isolated from mice to demonstrate the role of Hic-5 in the regulation of PSCs activation, proliferation and migration. Finally, we investigated the effect of NF-κB/p65 on CP development by inhibiting NF-κB/p65 with triptolide, an immunosuppressant diterpenoid epoxide. 
| MATERIAL S AND ME THODS

| Patients and tissue specimens
| Construction of experimental model
Hic-5 KO mice are produced by Beijing Biocytogen Co., Ltd. Wild-type (WT) and systemic Hic-5 knockout (Hic-5 KO) mice (C57BL/6 background) were maintained under specific pathogen-free conditions in the laboratory animal centre of Southwest Medical University.
Experiments were performed with age-and-sex matched mice at 8-12 weeks of age. Chronic pancreatitis (CP) was induced by repeated intraperitoneal injections of cerulein (Med Chem Express, MCE), 50 μg/ kg hourly, by a modification of the method described by Westphalen et al 23 Six hourly injections given in one day constituted one treatment. Treatments were given every other day for a total of six weeks.
Triptolide-treated model was induced in mice through intraperitoneal injection of triptolide (100 µg/kg, Med Chem Express, MCE) after twoweek cerulein treated, by a modification of the method described by Li et al 24 Injections were given six times per week for a total of four weeks. 
| Cells isolation
Pancreatic stellate cells were isolated from mice pancreas by collagenase digestion and Nycodenz density gradient centrifugation. and antibiotics (penicillin 100 U/mL and streptomycin 100 mg/mL, Invitrogen). Cells were maintained in a humidified atmosphere of 5% CO 2 at 37°C. After reaching 80% confluence, cells were briefly trypsinized (0.25% Trypsin-EDTA, Invitrogen) and subcultured. Cells were used before the first passage. Primary pancreatic acini were isolated from mice pancreas by collagenase digestion under sterile conditions, as previously reported. 26 Isolated acini were cultured in RPMI-1640 medium containing penicillin (50 U/mL) and streptomycin (50 μg/mL) supplemented with 10% serum at 37°C in a 5% CO 2 atmosphere.
| RNA isolation, reverse-transcription and quantitative real-time polymerase chain reaction (qRT-PCR)
RNA isolation and the PCR amplification conditions were followed as manufacturer's instructions (Toyobo, Osaka, Japan). Real-time PCR was performed to quantify the expression of several genes in cultured cells and pancreatic tissues using a real-time PCR detection system (LightCycler 96, Roche). Samples were run in triplicates, expression values were normalized against RPL-13A genes, 27, 28 and fold changes were calculated to the control group using the 2 −ΔΔCT method. Gene-specific primers were described in Table 1 . 
| Western blot analysis
| Cell proliferation assay
PSCs were seeded at a density of 5000 cells per well in E-Plate L8 
| Wound healing assay
Cells were seeded into a 6-well plate and allowed to grow to full confluence. To study migration, a scratch was made on the culture plate using 
| Transwell migration assay
Migration assays were carried out by using Transwell chambers with pore polycarbonate filters (8.0 mm; Corning), which were inserted in a 24-well plate. In brief, cells in serum-free medium were added to the upper chamber. Medium with 10% foetal bovine serum as the chemoattractant was placed in the lower chamber. The plates were incubated for 24 hours at 37°C in 5% CO 2 ; afterwards, cells that did not migrate via the pores were removed by wiping them with a cotton swab. Cells left on the lower surface of the membrane were stained with 0.1% crystal violet. At last, we cleaned the upper chamber and inverted the chamber, counted the number of cells on the lower surface of the membrane.
| Haematoxylin and eosin staining, Masson's trichrome staining and Sirius Red staining
Pancreatic tissues from killed mice were immediately fixed in 4%
paraformaldehyde for paraffin embedding. Paraffin sections were Sections were dehydrated and sealed, then examined using a microscope (Olympus).
| Immunohistochemistry
| Immunofluorescence
The cells were permeabilized in 0.1% Triton-X/PBS for 20 minutes at room temperature. After incubation with anti-Hic5, anti-NF-κB/ p65 or anti-α-SMA for overnight at 4°C in a dark place, the cells were washed with PBS for three times. Then, the cells were incubated with secondary antibodies for 1 hour, and 4′6-diamino-2-phenylindole (DAPI, Beyotime) was added to stain the cell nuclei. The cells were detected by a laser scanning confocal microscope (Olympus).
| ELISA
Serum amylase and IL-6 levels were assayed by ELISA kit according to the manufacturer's instructions (Catalog No. MU20882, MU30044, R&D Systems).
| Statistical analysis
Animals were randomly allocated to control and treatment groups.
All data were collected from three independent experiments. All data were expressed as means ± the standard error of the mean.
Statistical analysis was performed with GraphPad Prism 6.0 software, and analysis of Student's t test was used to evaluate statistical significance. Differences are considered significant when *P < .05, **P < .01, ***P < .001 and ns P > .05.
| RE SULTS
| Pancreatic Hic-5 expression is induced in CP
Since most patients with chronic pancreatitis who visit our hospital do not need surgery, we regret that there are only two specimens of chronic pancreatitis. We used these specimens for haematoxylin and eosin (H&E) staining and found that compared to the normal person, the necrotic and inflammatory areas in pancreas of patients with CP were markedly increased ( Figure 1A ). Next, we evaluated 
TA B L E 1 Sequence (5′-3′) of primers used in this study was significantly increased in the mice with CP compared to the untreated mice by immunohistochemistry ( Figure 2B ,2). Furthermore, qRT-PCR and Western blot analysis confirmed that the mRNA and protein expression levels of Hic-5 in the pancreas were markedly increased in the CP mice compared to the untreated mice ( Figure 2D ,2).
| Knockout of Hic-5 attenuates cerulein-induced CP in vivo
To investigate the contribution of Hic-5 to the development of CP, we induced CP in wild-type and Hic-5 KO mice by cerulein. After treatment of mice with cerulein, we found that the pancreas size and weight in the Hic-5 KO mice were significantly increased compared to the wild-type mice ( Figure 3A and 3) . Histological examination of the H&E-stained pancreatic sections indicated that the necrotic and inflammatory areas were significantly reduced in the Hic-5 KO mice compared with the wild-type mice after cerulein treatment ( Figure 3C ). Sirius Red and Masson's trichrome staining used for morphometric analysis of the pancreatic fibrosis revealed that the pancreatic fibrosis was significantly reduced in the Hic-5 KO mice compared with the wild-type mice after treatment with cerulein, based on both staining methods ( Figure 3D,3) . We next analysed serum levels of amylase and IL-6 by ELISA and confirmed that the levels of amylase and IL-6 in the peripheral blood of the Hic-5 KO mice treated with cerulein were significantly lower than those of the wild-type mice treated with cerulein ( Figure 3F ).
| Knockout of Hic-5 decreases the expression of cerulein-induced pancreatic fibrosisrelated factors and NF-κB/p65 in vivo
Immunohistochemical analysis of the pancreas sections indicated that the expression of α-SMA, a marker for activated PSCs, 29 was significantly decreased in the pancreas of Hic-5 KO mice treated with cerulein compared with the wild-type mice treated with cerulein ( Figure 4A ). We evaluated the mRNA levels of fibrosis-associated and Timp1 in the pancreas of the Hic-5 KO mice were significantly lower than those of the wild-type mice, following cerulein treatment ( Figure 4B ). Interestingly, there was no difference in the mRNA expression of TGF-β between the wild-type and the Hic-5 KO mice after cerulein treatment ( Figure 4B ). In addition, Western blot analysis confirmed that the expression of α-SMA and Col1a1 in the pancreas of the Hic-5 KO mice was significantly lower than that of the wild-type mice after cerulein treatment ( Figure 4C ). These results indicated that Hic-5 deficiency contributed to the improvement observed in mice with cerulein-induced CP. Besides, we evaluated the mRNA and protein levels of the NF-κB/p65 subunit and IL-6 in the pancreas by qRT-PCR and Western blot analysis. We found that the expression levels of NF-κB/p65 and IL-6 were higher in the pancreas of the cerulein-treated wild-type mice compared with the untreated mice and that their expression levels were significantly decreased in the pancreas of the cerulein-treated Hic-5 KO mice ( Figure 4D,4) .
Also, as shown in the result of immunofluorescence ( Figure 4F) and immunohistochemistry ( Figure S1A ) for NF-κB/p65, the total expression level and nuclear expression level of NF-κB/p65 in the pancreas of cerulein-treated Hic-5 KO mice were significantly lower than that of cerulein-treated WT mice ( Figures 4F and S1A ). Our immunohistochemistry for IκB-α suggested there were no significant differences in IκB-α expression between cerulein-treated Hic-5 KO mice and cerulein-treated WT mice ( Figure S1B ). , and IL-6 and NF-κB/p65 (D). C, E, Representative Western blot analyses for Hic-5, α-SMA, and Col1a1 (C), and IL-6 and NF-κB/p65 (E) in the pancreas of WT and Hic-5 KO mice. F, Representative images of the immunofluorescence for NF-κB/p65 in WT mice and Hic-5 KO mice with CP induced by cerulein. Scale bar, 100 μm.*P < .05, **P < .01, ***P < .001, by two-tailed, unpaired Student's t test. (n = 5) Figure 5A ). The activation of PSCs plays a crucial role in promoting ECM production and pancreatic fibrosis. 29 Therefore,
F I G U R E 2
| Hic-5 deficiency inhibits TGF-β-induced PSCs activation and NF-κB/p65 expression
we assessed whether with the wild-type PSCs ( Figure 5C ). Next, we analysed the migration ability of the cells using a wound healing and transwell migration assay.
We found that the migration ability of the Hic-5 KO PSCs was significantly decreased compared to wild-type PSCs with or without TGF-β stimulation ( Figure 5D ,E). We also found that the wild-type PSCs exhibited high expression levels of fibrosis-associated proteins, including α-SMA, Col1a1, and vimentin, and that the expression levels for these proteins were significantly decreased in Hic-5 KO PSCs ( Figure 5F ).
Furthermore, the protein levels of NF-κB/p65 and IL-6 were significantly decreased in the Hic-5 KO PSCs compared with the wild-type PSCs ( Figure 5F ). These results indicated that the activation of PSCs was mediated through Hic-5 expression and that NF-κB/p65 may be involved in the development of CP in mice treated with cerulein.
| Triptolide attenuates the activation of cultured PSCs by inhibiting NF-κB/p65 expression
To determine whether NF-κB/p65 was involved in the development of CP, we treated primary PSCs cultures with different concentrations of the NF-κB/p65 inhibitor triptolide, as described previously. 24 Triptolide led to a significant and dose-dependent reduction in the proliferation of PSCs compared to the untreated PSCs ( Figure 6A ). The protein levels of the related factors in PSCs were assessed by immunofluorescence. We found that the expression levels of NF-κB/p65 and α-SMA, which were high in control PSCs, were significantly decreased in a dose-dependent manner in PSCs treated with triptolide ( Figure 6B ). In addition, analysis of the cultures for cell migration ability by the wound healing and transwell migration assay demonstrated that triptolide decreased the ability of PSCs to metastasize in a dose-dependent manner compared to the control PSCs ( Figure 6C,6 ). We also evaluated the protein levels of related factors in PSCs by Western blot analysis. The control PSCs exhibited high expression levels of the fibrosis-associated proteins including α-SMA, Col1a1, and vimentin, as well as NF-κB/p65 and IL-6, and the expression levels of these factors were significantly decreased in a dose-dependent manner in the PSCs treated with triptolide ( Figure 6E ).
| Triptolide alleviates cerulein-induced CP in vivo
To explore the therapeutic potential of targeting NF-κB/p65 in ce- Figure 7E ). We also analysed the serum level of IL-6 by ELISA and confirmed that the level of IL-6 was significantly lower in the peripheral blood of mice treated with triptolide than those treated with saline ( Figure 7F ).
| Triptolide reduces the increased expression of cerulein-induced pancreatic fibrosisrelated factors and NF-κB/p65 in vivo
Immunohistochemistry of the pancreatic sections indicated the expression of α-SMA was significantly decreased in the pancreas of the triptolide-treated mice compared to the saline-treated mice ( Figure 8A ). We also evaluated the mRNA levels of fibrosis-associated 
| D ISCUSS I ON
The results of the current study demonstrate Hic-5 as a key The role of various cells and pathways in the pancreatic microenvironment of CP, especially the role of NF-κB signalling, has been studied extensively. [35] [36] [37] PSCs are now recognized as the key mediators of pancreatic fibrosis. However, the role of NF-κB in PSCs during the progression of CP has not been studied. In a study of hepatic stellate cells and liver fibrosis, the authors reported that the mechanism underlying liver fibrosis involved TNF-α, which mediated NF-κB activation in hepatic stellate cells and increased the ability of these cells to produce inflammatory cytokines. 38 In the present study, we found that the levels of NF-κB/p65 and IL-6 were significantly increased in the cerulein-induced CP mice model in vivo and in activated PSCs in vitro. Importantly, knockout of Hic-5 also significantly reduced the expression levels of NF-κB/p65 and IL-6 in the cerulein-induced CP model in vivo and activated PSCs in vitro.
Triptolide is a diterpenoid epoxide with the immunosuppressant activity that is an extract of the Chinese herbal medicine Tripterygium wilfordii. Triptolide was previously shown to inhibit the NF-κB transcriptional activity and reduce NF-κB/p65 protein levels by disrupting the interaction of NF-κB/p65 with CREB-binding protein. 39 Therefore, we determined whether reducing NF-κB/ p65 levels by triptolide could alleviate CP. Interestingly, the activation, proliferation and migration of the PSCs were inhibited after treatment of PSCs with triptolide, whereas the down-regulation of NF-κB/p65 resulted in a significant reduction in fibrosis in mice, as demonstratedby Sirius Red and Masson's trichrome staining. The inhibition of NF-κB/p65 not only reduced the activation of the PSCs but also led to a significant decrease in the expression of IL-6 and downstream ECM-related proteins (Figure 7 ). This finding is consistent with previous studies demonstrating that the activation of NF-κB/p65 directly regulated IL-6 production and promoted inflammation. 40, 41 Importantly, triptolide is currently in clinical use and was shown to be beneficial in mice models of polycystic kidney disease 42 and pancreatic cancer in vitro and in vivo. As a drug-treated polycystic kidney disease and adjuvant therapy for human immunodeficiency virus-1, phase III clinical trials are currently underway. 43, 44 Our findings in the current study suggest that the clinically used triptolide doses might also provide benefit in patients with CP.
In conclusion, the current study using both in vitro and in vivo approaches is the first to demonstrate the role of Hic 
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